Mice intradermally-inoculated with the intact lipopolysaccharide, but not the lipid A or O-chain, from Francisella tularensis LVS rapidly acquire varying degrees of enhanced resistance against systemic or aerogenic challenge with virulent strains of the pathogen

Microbial Pathogenesis

Volumn 34, Issue 1, 2003, Pages 39-45

  Conlan, J Wayne ^a   Vinogradov, Evguenii ^a   Monteiro, Mario A ^a,b   Perry, Malcolm B ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b PFIZER INC   (United States)

Author keywords

Aerosol; Francisella tularensis; Host defense; Lipopolysaccharide

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; LIPID A; O ANTIGEN;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL IMMUNITY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FRANCISELLA TULARENSIS; HOST PATHOGEN INTERACTION; HOST RESISTANCE; IMMUNIZATION; IMMUNOGENICITY; INFECTION RESISTANCE; INOCULATION; LIPID HYDROLYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

BACTERIA (MICROORGANISMS); FRANCISELLA TULARENSIS;

EID: 0037215101     PISSN: 08824010     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0882-4010(02)00194-8     Document Type: Article

References (25)

1. Tärnvik A. Nature of protective immunity to Francisella tularensis. Rev Infect Dis. 11:1989;440-451.
2. Tärnvik A.M., Ericsson M., Sandström G., Sjöstedt A. Francisella tularensis - a model for studies of the immune response to intracellular bacteria in man. Immunology. 76:1992;349-354.
3. Tärnvik A., Ericsson M., Golovliov I., Sandström G., Sjöstedt A. Orchestration of the protective immune response to intracellular bacteria: Francisella tularensis as a model organism. FEMS Immunol Med Microbiol. 13:1996;221-225.
4. Saslaw S., Eigelsbach H.T., Prior J.A., Wilson H.E., Carhart S. Tularemia vaccine study.II. Respiratory challenge. Arch Intern Med. 107:1961;689-701.
5. 8+ T-cell-dependent and -independent host defense mechanisms can operate to control and resolve primary and secondary Francisella tularensis LVS infection in mice. Infect Immun. 62:1994;5603-5607.
6. Elkins K.L., Rhinehart-Jones T.R., Nacy C.A., Winegar R.K., Fortier A.H. T-cell-independent resistance to infection and generation of immunity to Francisella tularensis. Infect Immun. 61:1993;823-829.
7. 8+ T cells does not affect the magnitude of protective immunity to an intracellular pathogen, Francisella tularensis strain LVS. Immunology. 157:1996;5042-5048.
8. Fulop M., Mastroeni P., Green M., Titball R.W. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine. 19:2001;4465-4472.
9. Fortier A.H., Narayanan R.B., Drabick J., Williams J.C., Nacy C.A. Vaccination with lipopolysaccharide isolated from the live vaccine strain of Francisella tularensis protects against murine tularemia. Vaccine Res. 5:1996;193-202.
10. Dreisbach V.C., Cowley S., Elkins K.L. Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon. Infect Immun. 68:2000;1988-1996.
11. Sandstrom G., Sjostedt A., Johansson T., Kuoppa K., Williams J.C. Immunogenicity and toxicity of lipopolysaccharide from Francisella tularensis LVS. FEMS Microbiol Immunol. 105:1992;201-210.
12. Conlan J.W., KuoLee R., Shen H., Webb A. Different host defenses are required to protect mice from primary systemic versus pulmonary infection with the facultative intracellular bacterial pathogen, Francisella tularensis LVS. Microbial Pathogenesis. 32:2002;127-134.
13. Johnson K.G., Perry M.B. Improved techniques for the preparation of bacterial polysaccharides. Can J Microbiol. 22:1976;29-34.
14. Zahringer U., Lindner B., Rietschel E.T. Chemical structure of Lipid A: recent advances in structural analysis of biologically active molecules. Brade H., Opal S.M., Vogel S.N., Morrison D.C. Endotoxin in health and disease. 1999;93-114 Marcel Dekker, New York.
15. Vinogradov E.V., Perry M.B., Conlan J.W. Structural analysis of Francisella tularensis lipopolysaccharide. Eur J Biochem. 269:2002;6112-6118.
16. Vinogradov E.V., Shashkov A.S., Knirel Y.A., Kochetkov N.K., Tochtamysheva N.V., Averin S.F., Goncharova O.V., Khlebnikov V.S. Structure of the O-antigen of Francisella tularensis strain 15. Carbohydr Res. 214:1991;289-297.
17. MacKenzie C.R., Perry M.B., McDonald I.J. Structure of the D-glucan produced by Neisseria perflava. Can J Microbiol. 24:1978;1419-1422.
18. Riou J.-Y., Guibourdenche M., Perry M.B., MacLean L.L., Griffith D.W. Structure of the exocellular D-glucan produced by Neisseria polysaccharea. Can J Microbiol. 32:1986;909-911.
19. Hetland G., Ohno N., Aaberge I.S., Lovik M. Protective effect of beta-glucan against systemic Streptococcus pneumoniae infection in mice. FEMS Immunol Med Microbiol. 27:2000;111-116.
20. Takahashi H., Ohno N., Adachi Y., Yadomae T. Association of immunological disorders in lethal side effects of NSAIDs on beta-glucan-administered mice. FEMS Immunol Med Microbiol. 31:2001;1-14.
21. Young S.H., Ye J., Frazer D.G., Shi X., Castranova V. Molecular mechanism of tumor necrosis factor-alpha production in 1-3-beta-glucan (zymosan)-activated macrophages. J Biol Chem. 276:2001;20781-20787.
22. Conlan J.W., North R.J. Early pathogenesis of infection in the liver with the facultative intracellular bacteria, Listeria monocytogenes, Francisella tularensis, and Salmonella typhimurium involves lysis of infected hepatocytes by leukocytes. Infect Immun. 60:1992;5164-5171.
23. Fitzgeorge R.B., Baskerville A., Broster M., Hambleton P., Dennis P.J. Aerosol infection of animals with strains of Legionella pneumophila of different virulence: Comparison with intraperitoneal and intranasal routes of infection. J Hyg (Camb). 90:1983;81-89.
24. MacLean L.L., Perry M.B. Structural studies on the O-polysaccharide of the lipopolysaccharide produced by Citrobacter rodentium (ATCC 51459). Eur J Biochem. 268:2001;5740-574625.
25. Ciucanu I., Kerek F. A simple rapid method for the permethylation of carbohydrates. Carbohydr Res. 131:1984;209-217.